Early diagnosis of venous thromboembolism in cancer patients

BioMark / Sensor Research, an I&D group from ISEP, is leading the project STRIP2SENSE, which aims the production of test strips for screening and early diagnosis of venous thromboembolism biomarkers in cancer patients. This is a brand new technology, portable, low-price, and with a quick action in real-time.

The venous thromboembolism includes the deep venous thrombosis and pulmonary embolism, and it’s characterized by the formation of clots that avoid the normal circulation of blood flow. The cancer’s biology and therapeutic approaches are related with coagulation processes, which results in a clinical problem due the risk of oncology patients develop this disease, and that could aggravate the prognosis of cancer. So, in this context, it is extremely important the production of new devices, that allow an early diagnosis, and more accurately, of venous thromboembolism.

“This project aims the development of disposable test strips to detect altered levels of certain biomarkers in biological fluids and thus determine the risk of oncological patients presenting venous thromboembolism. This technology is non-invasive and low cost, which works as an advantage for the patients”, explains the Professor and researcher of BioMark/Sensor Research, Manuela Frasco.

With this new solution the ISEP’s team want to improve the quality of life of patients with cancer. At the same time, it is expectable the contribution for a more efficient management of the wealth resources.

The project officially started on October of last year and it will go on until April of 2019. Besides ISEP, there are involved another partners such as: IPATIMUP and INL. The total funding for STRIP2SENSE is around 150.000 euros with the support of FCT.